Hefei Lifeon Pharmaceutical (SZ:003020) Hu Xiu·2025-05-13 04:20Core Viewpoint - The article discusses the rising trend of using "smart drugs" in high-pressure industries like finance and technology, highlighting both the demand for these drugs and the associated risks of misuse and legal issues [1][2][3]. Group 1: Market Dynamics - The first domestic "smart drug" was launched in April, leading to a surge in stock prices for the company, Lifan Pharmaceutical, which experienced five consecutive trading limit increases [2][37]. - The global ADHD medication market is projected to reach $14.71 billion by 2025, with a compound annual growth rate of 4.11%, potentially reaching $21.14 billion by 2034 [35]. - The only officially approved "smart drug" in China, "Zhuanzhu Da," has faced supply shortages due to high demand and limited production capacity [27][30]. Group 2: Usage and Misuse - "Smart drugs" are primarily used by individuals seeking to enhance focus and productivity, often leading to illegal procurement methods and health risks [6][10][12]. - Reports indicate that a significant number of young professionals and students are using these drugs to cope with academic and work pressures, with some resorting to illegal channels for acquisition [15][16][23]. - The misuse of these drugs can lead to addiction and various health issues, including anxiety, depression, and cardiovascular problems [19][46]. Group 3: Regulatory and Ethical Concerns - The strict regulation of "smart drugs" in China limits access for legitimate ADHD patients, creating a paradox where those in need cannot obtain the medication [23][24]. - The article highlights the ethical dilemma surrounding the use of "smart drugs," as they do not genuinely enhance cognitive abilities but merely increase focus temporarily [45].